Ampicillin Mylan 1 g Norge - norsk - Statens legemiddelverk

ampicillin mylan 1 g

mylan hospital as - ampicillinnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 1 g

Ampicillin Mylan 2 g Norge - norsk - Statens legemiddelverk

ampicillin mylan 2 g

mylan hospital as - ampicillinnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 2 g

Carduran CR 4 mg Norge - norsk - Statens legemiddelverk

carduran cr 4 mg

upjohn eesv - doksazosinmesilat - depottablett - 4 mg

Carduran CR 8 mg Norge - norsk - Statens legemiddelverk

carduran cr 8 mg

upjohn eesv - doksazosinmesilat - depottablett - 8 mg

Acitretin Orifarm 25 mg Norge - norsk - Statens legemiddelverk

acitretin orifarm 25 mg

orifarm generics a/s - acitretin - kapsel, hard - 25 mg

Acitretin Orifarm 10 mg Norge - norsk - Statens legemiddelverk

acitretin orifarm 10 mg

orifarm generics a/s - acitretin - kapsel, hard - 10 mg

Kiovig 100 mg/ ml Norge - norsk - Statens legemiddelverk

kiovig 100 mg/ ml

orifarm as - immunglobulin (humant) - infusjonsvæske, oppløsning - 100 mg/ ml

TechneScan MAG3 1 mg Norge - norsk - Statens legemiddelverk

technescan mag3 1 mg

curium netherlands b.v. - betiatid - preparasjonssett til radioaktive legemidler - 1 mg

Nyxthracis (previously Obiltoxaximab SFL) Den europeiske union - norsk - EMA (European Medicines Agency)

nyxthracis (previously obiltoxaximab sfl)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - immune sera og immunglobuliner, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Rekambys Den europeiske union - norsk - EMA (European Medicines Agency)

rekambys

janssen-cilag international nv - rilpivirine - hiv-infeksjoner - antivirale midler til systemisk bruk - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.